Cologuard® Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
October 30, 2015 8:32 AM EDTRoth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00), following the company's 3Q earnings results and guidance. Management introduced 4Q volume guidance of 42k tests. EXAS also introduced 2016 volume and revenue guidance of 240k and... More
Exact Sciences (EXAS) Misses Q3 EPS by 1c
October 29, 2015 8:25 AM EDTExact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.45), $0.01 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $12.56 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
... More